Pacira BioSciences, Inc. (PCRX) — ESG & Values Scores

Environment story

Pacira BioSciences discloses minimal environmental metrics in its 10-K filing. The company acknowledges use of hazardous materials and compliance with environmental laws but provides no quantified Scope 1, 2, or 3 emissions data, renewable energy percentage, or net-zero commitments. Risk factors mention climate change and water availability risks but lack concrete mitigation strategies or targets. Manufacturing operations in San Diego and Swindon, UK involve chemical production and batch processing typical of pharmaceutical manufacturing, but no environmental controversies, fines, or toxic-waste litigation are disclosed. The absence of third-party sustainability reporting or ESG disclosures suggests limited environmental accountability infrastructure.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Manufacturing efficiency improvements

Decommissioned 45-liter batch manufacturing suite at Science Center Campus and consolidated to large-scale 200+ liter suites in San Diego and Swindon, UK to reduce manufacturing waste and improve operational efficiency.

Estimated annual operating expense reduction of $13.0 million; reduced batch waste per unit through larger-scale process.
Hazardous materials compliance

Company states it must comply with environmental laws and regulations related to hazardous materials used in pharmaceutical manufacturing.

Social story

Pacira BioSciences discloses limited social metrics in its 10-K. The company does not report CEO-to-median-worker pay ratios, workforce turnover rates, or detailed diversity statistics (gender/race/ethnicity percentages). No evidence of union-suppression activities, strikes, or major labor disputes within the last 24 months is disclosed. July 2025 reduction in force of 71 employees (8% of workforce) at Science Center Campus was driven by manufacturing optimization, not labor conflict, and included severance and healthcare continuation under California law. No supply-chain human-rights audits, conflict-minerals policies, or living-wage commitments are explicitly disclosed. Supply chain consists of third-party contract manufacturers (Thermo Fisher, LG Chem partnership announced 2026) and raw material suppliers sourced globally, but no detailed labor or ethics audits are documented in the filing.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Workforce reduction with severance protections

July 2025 reduction of 71 employees at Science Center Campus included garden leave under California employment law, severance, healthcare benefits continuation, and termination benefits totaling $3.7 million.

Transition support provided to affected workers; $13.0 million annual operating expense reduction achieved through manufacturing consolidation.
Third-party contract manufacturer partnerships

Partnerships with Thermo Fisher and LG Chem for manufacturing and commercialization; agreements include quality standards and compliance requirements.

Governance story

Pacira BioSciences operates with a single-class common stock structure (no dual-class voting), which supports governance equity. Board independence metrics are not explicitly disclosed in the 10-K, though a January 2026 appointment of an independent director (Dr. Samit Hirawat, formerly BMI CMO) to a 10-member board suggests robust independent representation, though specific independence percentage is undisclosed. Lobbying expenditures are not reported in the filing; no evidence of anti-environmental or consumer-protection deregulation lobbying is disclosed. Company faces active IP litigation: November 2025 patent infringement suits against generic ANDA filers (WhiteOak and Qilu) for EXPAREL; April 2025 U.S. District Court ruling invalidated an EXPAREL patent but issued favorable judgment ordering RDF repayment of royalties ($23.1 million gain recognized). No antitrust, consumer-safety, or major financial-fraud regulatory proceedings are disclosed. Company operates under standard pharmaceutical regulatory oversight (FDA approvals, clinical trial compliance).

Criticisms on file

Patent infringement litigation – EXPAREL generics
Source: PCRX 10-K MD&A (November 2025); Note 20 Commitments and Contingencies
EXPAREL patent invalidity ruling – District Court of Nevada
Source: PCRX 10-K Goodwill Impairment section (August 2024 ruling); Impact on 2024 $163.2 million goodwill impairment
RDF royalty dispute – favorable judgment with pending appeal
Source: PCRX 10-K MD&A Other Income section; Note 20 Commitments and Contingencies (April 2025 ruling; May/September 2025 appeals filed)

Disclosed initiatives

Board expansion with independent expertise

January 2026 appointment of Dr. Samit Hirawat (former BMI Executive VP, Chief Medical Officer) to board and Science and Technology Committee; increases board size to 10 members.

Strengthens clinical development and drug-development oversight; brings 25+ years industry expertise.
Intellectual property defense

November 2025 filed patent infringement suits against WhiteOak and Qilu for EXPAREL ANDA filings; April 2025 favorable judgment from U.S. District Court (Nevada) requiring RDF repayment of royalties totaling $23.1 million, with appeal pending by RDF.

Protects EXPAREL market exclusivity; recovers $23.1 million in contested royalties; ongoing legal costs for defense of IP.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Pacira BioSciences, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Pacira BioSciences, Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)